Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myeloma

Initiation of a Phase II trial in multiple myeloma evaluating the combination of IPH 2101 - a fully human anti-KIR monoclonal antibody stimulating NK cells' anti-tumoral activity, with Celgene’s REVLIMID® Growing body of evidence in hematological malignancies supports REVLIMID® enhanced NK-mediated cytotoxicity and its potential synergy with IPH 2101’s mechanism of action Subscribe to our newsletter Contact us 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30

The release as fetched from its publisher. innate-pharma.com ↗